INGN Company Profile and Key Details

INGN has shown mixed momentum, losing 0.0% over the past week and -25.81% over the past quarter, though year-to-date performance is down -7.59%. Short-term trend indicators are bullishly aligned (SMA20 -7.32%, SMA50 -14.38%, SMA200 -21.59%). The stock’s 14-day RSI is 30.17 (weak momentum), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -53.18% below its high and over -0.53% above its low. Average 10-day trading volume of 213.98 thousand shares is slightly above the 3-month average of 189.36 thousand, indicating heightened recent market interest.

Inogen, Inc. has 27.04 million shares outstanding. The public float is 23.96 million shares, elevated short interest at 3.33% of float. This equals 892.30 thousand shares. The short ratio is 5.11 days. Institutional investors hold 85.45% of the float. Insiders own 12.08%. Novo Holdings A/S holds 2.08 million shares, Smith Kevin Raymond Merrill has 70.27 thousand shares and Taylor Brenton has 56.86 thousand shares.

Wall Street analysts project EPS growth of 25.65% annually over the next five years. The latest quarter delivered EPS of -$0.20. The next quarter is forecast at -$0.36. Next year's EPS is expected at $33.08. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $14.00. The high target offers 150.45% upside. The low target suggests 150.45% downside. The mean target is $14.00. This offers 150.45% upside. Inogen, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 05, 2025, missed forecasts by -8.88%. The prior quarter beat by -31.82%. Over the last six quarters, Apple has recorded several small beats. These include -55.56% in August 06, 2024.

Inogen, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.36. This means the shares are trading below this model’s fair value.

Inogen, Inc. (NASDAQ:INGN) shares are flat -7.59% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Inogen, Inc. trading at a premium to the broader market with a P/E of -5.73. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $98.52, suggesting 1662.43% upside. Our AI forecast model points to short-term weakness (-8.77% over two weeks), a medium-term fall (-66.01% over three months), and a longer-term gain (2.15% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Inogen, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.77%, with price expected at $5.10 by February 20, 2026, within a range of $4.85 to $5.34 3-Month Outlook: Projected fall of -66.01%, reaching $1.90 by May 07, 2026, with a range of $1.64 to $2.11. 1-Year Outlook: Projected gain of 2.15%, with price at $5.71 by February 05, 2027, within a range of $0.00 to $3.80.

Inogen, Inc. (NASDAQ:INGN) closed at $5.59 USD, losing -$0.07 (-1.24%) from the previous close of $5.66. The stock is currently within 5% of its 52-week low $5.48 and $11.94. With a market capitalization of about $151.76 million, Inogen, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.79). Key stats such as the average daily volume over the past year has been around 189.29 thousand shares, in line with its 52-week average. Headquartered in Goleta, CA, Inogen, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Kevin R. Smith, the company employs approximately 766 people and listed since February 14, 2014. Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally.

Inogen, Inc. trades at a P/E ratio of -5.73, slightly below the S&P 500 average, with a price-to-sales ratio of 0.43 and a price-to-book ratio of 0.74 suggesting the stock is closer to book value. The P/FCF stands at -6.12, also below market averages.